A lot of work over years has clearly gone in pre-IPO in terms of successful product development to set up for inflection points post-IPO. It really is now a short time to wait for commercialisation in Bio-tech timeframes (or for most industries for that matter) assuming no further trials are required which is how the company has positioned it. I feel a lot more eyes will be on this as each week passes, particularly as initial results on the pivotal study has been released to be followed by final results.
A lot of work over years has clearly gone in pre-IPO in terms of...
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
76.0¢ |
Change
0.030(4.11%) |
Mkt cap ! $52.80M | |||
| Open | High | Low | Value | Volume |
| 73.5¢ | 78.5¢ | 73.5¢ | $131.7K | 171.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 663 | 75.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 76.0¢ | 14564 | 1 |
View Market Depth
| Last trade - 13.16pm 26/06/2024 (20 minute delay) ? |
| LTP (ASX) Chart |